Deutsch English Français

Contact

EP3525803

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3525803

EP3525803 - IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 13.10.2023 Database last updated on 12.07.2024
Former	The patent has been granted Status updated on 04.11.2022
Former	Grant of patent is intended Status updated on 21.06.2022
Former	Examination is in progress Status updated on 22.04.2022
Former	Grant of patent is intended Status updated on 13.12.2021
Former	Examination is in progress Status updated on 26.11.2021
Former	Grant of patent is intended Status updated on 13.07.2021
Former	Examination is in progress Status updated on 24.07.2020
Former	Request for examination was made Status updated on 19.07.2019
Former	The international publication has been made Status updated on 20.04.2018
Former	unknown Status updated on 01.12.2017
Most recent event Tooltip	07.06.2024	Lapse of the patent in a contracting state New state(s): MC	published on 10.07.2024 [2024/28]
Applicant(s)	For all designated states Juno Therapeutics, Inc. 400 Dexter Avenue North, Suite 1200 Seattle, WA 98109 / US
	[2019/34]
Inventor(s)	01 / PORTS, Michael c/o Juno Therapeutics Inc. 400 Dexter Ave. N. Suite 1200 Seattle, WA 98109 / US
	02 / THOMAS, Evan Paul c/o Juno Therapeutics Inc. 400 Dexter Ave. N. Suite 1200 Seattle, WA 98109 / US
	03 / LEVITSKY, Hyam I c/o Juno Therapeutics Inc. 400 Dexter Ave. N. Suite 1200 Seattle, WA 98109 / US
	[2019/34]
Representative(s)	Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[2022/49]
Former [2019/34]	Goodfellow, Hugh Robin Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
Application number, filing date	17801797.6	13.10.2017
	[2019/34]
	WO2017US56680
Priority number, date	US201662407776P	13.10.2016 Original published format: US 201662407776 P
	US201762514767P	02.06.2017 Original published format: US 201762514767 P
	[2019/34]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2018071873
	Date:	19.04.2018
	Language:	EN
	[2018/16]
	Type:	A2 Application without search report
	No.:	EP3525803
	Date:	21.08.2019
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 19.04.2018 takes the place of the publication of the European patent application.
	[2019/34]
	Type:	B1 Patent specification
	No.:	EP3525803
	Date:	07.12.2022
	Language:	EN
	[2022/49]
Search report(s)	International search report - published on:	EP	04.10.2018
Classification	IPC:	A61K35/17, A61K45/06, A61K48/00, A61K31/4245, C07K14/725, C12Q1/26, C12N5/0783, G01N33/574, A61P35/00, C07K14/705	[2021/31]
	CPC:	C12N5/0636 (EP,KR,US); A61K35/17 (KR,US); A61K31/405 (KR); A61K31/4245 (EP,KR,US); A61K39/4611 (EP); A61K39/4631 (EP); (+) A61K39/464412 (EP); A61K45/06 (EP); A61K48/00 (EP); A61P35/00 (EP,KR); C07K14/705 (EP,KR); C07K14/7051 (EP,KR,US); C12N15/907 (US); C12Y113/11011 (EP,KR); C12Y113/11052 (EP,KR); C12Y207/11001 (EP,KR); C12Y207/11013 (EP,KR); G01N33/57496 (EP,KR,US); A61K2239/38 (EP); A61K2239/57 (EP); A61K2300/00 (KR); C07K2319/03 (EP,KR,US); C12N2310/20 (US); C12N2502/30 (EP,KR); C12N2510/00 (EP,KR); C12N2740/16043 (EP,KR); G01N2333/57 (KR) (-)
	C-Set:	A61K31/4245, A61K2300/00 (EP); A61K39/464412, A61K2300/00 (EP)
	Former IPC [2019/34]	A61K35/17, A61K45/06, A61K48/00, A61K31/4245, C07K14/725, C12Q1/26, C12N5/0783, G01N33/574, A61P35/00
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/34]
Extension states	BA	09.05.2019
	ME	09.05.2019
Validation states	MA	09.05.2019
	MD	09.05.2019
Title	German:	IMMUNTHERAPIEVERFAHREN UND ZUSAMMENSETZUNGEN MIT TRYPTOPHAN-STOFFWECHSELWEG-MODULATOREN	[2019/34]
	English:	IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS	[2019/34]
	French:	MÉTHODES ET COMPOSITIONS D'IMMUNOTHÉRAPIE IMPLIQUANT DES MODULATEURS DE LA VOIE MÉTABOLIQUE DU TRYPTOPHANE	[2019/34]
Entry into regional phase	09.05.2019	National basic fee paid
	09.05.2019	Designation fee(s) paid
	09.05.2019	Examination fee paid
Examination procedure	09.05.2019	Examination requested [2019/34]
	09.05.2019	Date on which the examining division has become responsible
	09.12.2019	Amendment by applicant (claims and/or description)
	24.07.2020	Despatch of a communication from the examining division (Time limit: M06)
	03.02.2021	Reply to a communication from the examining division
	14.07.2021	Communication of intention to grant the patent
	24.11.2021	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	14.12.2021	Communication of intention to grant the patent
	20.04.2022	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	22.06.2022	Communication of intention to grant the patent
	01.11.2022	Fee for grant paid
	01.11.2022	Fee for publishing/printing paid
	01.11.2022	Receipt of the translation of the claim(s)
Divisional application(s)	EP22206063.4 / EP4190335
Opposition(s)	08.09.2023	No opposition filed within time limit [2023/46]
Fees paid	Renewal fee
	21.10.2019	Renewal fee patent year 03
	14.10.2020	Renewal fee patent year 04
	29.09.2021	Renewal fee patent year 05
	15.09.2022	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AL	07.12.2022
	AT	07.12.2022
	CZ	07.12.2022
	DK	07.12.2022
	EE	07.12.2022
	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	MC	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RO	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	SI	07.12.2022
	SK	07.12.2022
	SM	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
	IS	07.04.2023
	PT	10.04.2023
	[2024/28]
Former [2023/51]	AL	07.12.2022
	AT	07.12.2022
	CZ	07.12.2022
	DK	07.12.2022
	EE	07.12.2022
	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RO	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	SI	07.12.2022
	SK	07.12.2022
	SM	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
	IS	07.04.2023
	PT	10.04.2023
Former [2023/46]	AL	07.12.2022
	AT	07.12.2022
	CZ	07.12.2022
	DK	07.12.2022
	EE	07.12.2022
	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RO	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	SK	07.12.2022
	SM	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
	IS	07.04.2023
	PT	10.04.2023
Former [2023/39]	AL	07.12.2022
	AT	07.12.2022
	CZ	07.12.2022
	EE	07.12.2022
	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RO	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	SK	07.12.2022
	SM	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
	IS	07.04.2023
	PT	10.04.2023
Former [2023/38]	AL	07.12.2022
	AT	07.12.2022
	CZ	07.12.2022
	EE	07.12.2022
	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RO	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	SK	07.12.2022
	SM	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
	PT	10.04.2023
Former [2023/37]	AL	07.12.2022
	AT	07.12.2022
	CZ	07.12.2022
	EE	07.12.2022
	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RO	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	SM	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
	PT	10.04.2023
Former [2023/35]	AT	07.12.2022
	CZ	07.12.2022
	EE	07.12.2022
	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RO	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	SM	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
	PT	10.04.2023
Former [2023/34]	EE	07.12.2022
	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	SM	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
	PT	10.04.2023
Former [2023/33]	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	SM	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
Former [2023/29]	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	NL	07.12.2022
	PL	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
Former [2023/25]	FI	07.12.2022
	HR	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	PL	07.12.2022
	RS	07.12.2022
	SE	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
Former [2023/23]	FI	07.12.2022
	LT	07.12.2022
	LV	07.12.2022
	SE	07.12.2022
	NO	07.03.2023
	GR	08.03.2023
Former [2023/22]	FI	07.12.2022
	LT	07.12.2022
	SE	07.12.2022
	NO	07.03.2023
Former [2023/20]	LT	07.12.2022
	NO	07.03.2023
Cited in	International search	[XYI]WO2010008427 (LUDWIG INST FOR CANCER RES LTD [US], et al);
		[XDYI]WO2016026772 (IOMET PHARMA LTD [GB]);
		[XYI]US2016058845 (GEORGIOU GEORGE [US], et al);
		[XYI]WO2016146035 (SYZ CELL THERAPY CO [CN]);
	by applicant	US8252592
		US4235871
		US4452773
		US4501728
		US4690915
		US4795698
		US4837028
		US4897355
		US4946787
		US5019369
		US5049386
		WO9116024
		WO9117424
		US5200084
		US5219740
		US5356802
		EP0452342
		US5436150
		US5487994
		WO9613593
		WO9618105
		WO9853058
		WO9853059
		WO9853060
		WO9918129
		WO9960120
		WO0014257
		US6040177
		US6140081
		US6207453
		WO0216536
		US6410319
		US6451995
		US6453242
		US2002131960
		US6503717
		WO03016496
		WO03020763
		US6534261
		US6599692
		US2003170238
		US6689558
		WO2004033685
		WO2004045543
		WO2004048566
		US6794136
		US2005064474
		US2005186289
		US2005267061
		WO2006000830
		WO2006005185
		US7030215
		US7067317
		US7070995
		US7070934
		US2006188987
		US7098209
		WO2007004062
		US2007105907
		US2007116690
		US7253273
		US7262054
		US7265209
		US2007218528
	WO2008022286
	US7354762
	US7361635
	WO2008052352
	WO2008058178
	US7446190
	US7446179
	US7446191
	WO2009073620
	WO2009072003
	WO2010005958
	WO2010017132
	WO2010017179
	WO2010033140
	US2011003380
	US2011059502
	WO2011044186
	WO2011045341
	WO2011056652
	EP2331095
	WO2011091153
	US2011301073
	EP2420494
	US2012046324
	CN102579452
	WO2012129514
	WO2012142237
	US8324353
	US8339645
	EP2537416
	US2012329812
	US2013029988
	WO2013016488
	WO2013026837
	US8389282
	WO2013033068
	WO2013033085
	US8398282
	CN103070868
	WO2013071154
	US2013149337
	US8479118
	WO2013123061
	WO2013126726
	WO2013151707
	US2013287748
	WO2013166321
	US2013331370
	WO2014018423
	WO2014031687
	WO2014055668
	US8710237
	US2014120622
	EP2736337
	EP2750677
	EP2751086
	US8802374
	US8822647
	US2014271635
	WO2014150646
	WO2014150677
	WO2014159248
	US2014329795
	US2014329816
	WO2014186035
	US8911993
	WO2015002918
	WO2015006520
	EP2833879
	US2015057238
	US2015064154
	WO2015047978
	WO2015082499
	US2015175712
	WO2015119944
	WO2015155341
	WO2015161276
	WO2016012615
	WO2016024233
	US2016046596
	WO2016026772
	US2016060266
	WO2016051181
	CN105567690
	US2017051035
	WO1991US08442
	WO1994US05601

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p